STSA-1002 injection gains approval from the U.S. FDA to conduct clinical trials
Staidson (Beijing) Biopharmaceutical Co., Ltd. has received approval from the U.S. Food and Drug Administration (FDA), for the use of STSA-1002 injection, and independently developed antagonist of complement receptor signaling for the treatment of COVID-19 indications.